Ads are not configured at this scope yet
Full access
Psychopharmacology
Published Online: 28 March 2019

FDA Approves ADHD Drug Adhansia HR

Terri D’ArrigoAuthors Info & Affiliations
Volume 5, Number 3
https://doi.org/10.1176/appi.pn.2019.pp3a1
Track CitationsAdd to favorites
PDF/EPUB
The Food and Drug Administration (FDA) in February approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older. Adhansia XR is a central nervous system stimulant by Adlon Therapeutics L.P.
Four clinical studies evaluated the efficacy and safety of Adhansia XR in patients with ADHD: two clinical studies in adults, one analog classroom trial in children aged 6 to 12 years, and one safety and efficacy study in children aged 12 to 17 years. Patients in all studies achieved statistically significant improvement in symptoms while receiving Adhansia XR compared with placebo.
Adhansia XR will be available in six capsule strengths: 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg. The recommended starting dose for patients 6 years and older is 25 mg once daily, with titration in increments of 10 mg to 15 mg at intervals of no less than 5 days. ■

Information & Authors

Information

Published In

Go to Psychopharmacology
Volume 5 • Number 3 • March 28, 2019

History

Published online: 28 March 2019
Published in print: March 28, 2019

Keywords

  1. Food and Drug Administration
  2. FDA
  3. clinical trials
  4. Adhansia XR
  5. methylphenidate
  6. attention-deficit hyperactivity disorder
  7. ADHD

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.